Last reviewed · How we verify
NCT07248176
Universal CAR-T Cell Therapy for MM
NA trial testing Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection in Multiple Myeloma in 6 participants. Currently enrolling.
15 March 2027
Quick facts
| Lead sponsor | Bioray Laboratories |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 10 April 2025 |
| Primary completion | 15 March 2027 |
| Estimated completion | 18 April 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection — full drug profile →
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
- Multiple Myeloma in Relapse — all drugs for Multiple Myeloma in Relapse →
- Multiple Myeloma, Refractory — all drugs for Multiple Myeloma, Refractory →
Sponsor
Bioray Laboratories — full company profile →
Who can join
18 and older, any sex, with Multiple Myeloma or Multiple Myeloma in Relapse. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r/r multiple myeloma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07248176
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other Bioray Laboratories trials
Trials by the same sponsor.
- NCT07248163 — Universal CAR-T Cell Therapy for NHL · NA · recruiting
- NCT06298630 — Long-term Follow-up Study of BRL-101 for TDT · not yet recruiting
- NCT06633042 — The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD · Phase 1 · not yet recruiting
- NCT06300723 — Clinical Study of BRL-101 in Severe SCD · NA · enrolling by invitation
- NCT06287086 — Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07248176 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bioray Laboratories
- Last refreshed: 1 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07248176.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing